Given the widely confirmed roles of HRS and ALIX in regulating the formation of PD-L1-positive sEVs across various tumors, developing targeted small-molecule inhibitors against these proteins presents an exciting and valuable direction for sEV-based cancer therapeutic research [25]. The gene discussed is CD274; the disease is cancer.